Results 221 to 230 of about 7,204,743 (394)

Complement-Mediated Kidney Diseases: Role of Alternative Pathway in Glomerular Inflammation. [PDF]

Kidney Int Rep
Barratt J, Garred P, Lafayette RA, Zhang H, Floege J.   +4 more
europepmc   +1 more source

Mitochondrial Alternative Pathway-Associated Photoprotection of Photosystem II is Related to the Photorespiratory Pathway.

Plant and Cell Physiology, 2016
C. Watanabe, W. Yamori, S. Takahashi, I. Terashima, K. Noguchi   +4 more
semanticscholar   +1 more source

Alternative pathways in science and industry: activism, innovation, and the environment in an era of globalization; David J. Hess

, 2007
Bruno Milanez
openalex   +2 more sources

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Genetic variability shapes the alternative pathway complement activity and predisposition to complement-related diseases. [PDF]

Immunol Rev, 2023
Rodríguez de Córdoba S.
europepmc   +1 more source

Additional file 3 of Genome-wide transcriptome analysis of the early developmental stages of Echinococcus granulosus protoscoleces reveals extensive alternative splicing events in the spliceosome pathway

, 2021
Mohammad Ali Mohammadi, Majid Fasihi Harandi, Donald P. McManus, Mehdi Mansouri   +3 more
openalex   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

Alternative pathway-mediated tubular complement activation in human proteinuric kidney diseases: a proof-of-concept study. [PDF]

Clin Kidney J
Alkaff FF, Lammerts RGM, Tiller G, van den Heuvel MC, Bajema IM, Daha MR, van den Born J, Berger SP.   +7 more
europepmc   +1 more source

Correction to: Mathematical Modelling of Alternative Pathway of Complement System. [PDF]

Bull Math Biol, 2021
Bakshi S, Cunningham F, Nichols EM, Biedzka-Sarek M, Neisen J, Petit-Frere S, Bessant C, Bansal L, Peletier LA, Zamuner S, van der Graaf PH.   +10 more
europepmc   +1 more source

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

Molecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone, James Dunford, Eleanor Calcutt, Vicki Gamble, Filiz Senbabaoglu Aksu, Lorena Ligammari, Georgina Wherry, Giorgia Gaeta, John C. Christianson, Adrienne M. Flanagan, Udo Oppermann, Adam P. Cribbs   +11 more
wiley   +1 more source